2014 Disease Radiopharmaceuticals 
AuntMinnie
APRIL 4, 2024
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
AuntMinnie
DECEMBER 8, 2023
Suspicion of malignancy may be prompted by avid uptake of the radiopharmaceutical FDG on PET/CT imaging, according to study results delivered on November 27 at the RSNA meeting. Accurate diagnosis of organizing pneumonia is confounded by the co-existence of [the condition] with lung malignancies," Kim said.
Imaging Technology
JUNE 10, 2024
More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug. Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.
AuntMinnie
JUNE 9, 2024
Her research also contributed to FDA approval of Lu-177 DOTATATE for treating neuroendocrine tumors; recently, she and collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, which has been approved for human studies by the FDA as an Investigational New Drug (IND).
AuntMinnie
OCTOBER 25, 2024
His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia.
Global Radiology CME
DECEMBER 21, 2024
A nuclear medicine hepatobiliary scan was also performed (not shown) and demonstrated no radiopharmaceutical present in the gallbladder due to cystic duct obstruction. Interventional approaches to gallbladder disease. A transperitoneal route is favored in patients with coagulopathy or diffuse liver disease [1]. 2022;16(1):49-54.
Expert insights. Personalized for you.
92 
Let's personalize your content